
Big Pharma M&A set for mega year as patent expiries drive deal urgency. $XBI $IBB If the current pace holds, 2026 biopharma M&A could top $250 billion, making it the #2 year on record after 2019’s $328 billion. #biotech ca.finance.yahoo.com/news/bi…

Investor/trader focused primarily in the biopharma sector. Tweets are not investment advice and are not recommendations of any kind.

Big Pharma M&A set for mega year as patent expiries drive deal urgency. $XBI $IBB If the current pace holds, 2026 biopharma M&A could top $250 billion, making it the #2 year on record after 2019’s $328 billion. #biotech ca.finance.yahoo.com/news/bi…

$IGC Completes Six-Week Treatment Phase Of CALMA For All Its 170 Participants. Topline Data Anticipated During December /January Timeframe

$INO Submits Conditional MAA to European Medicines Agency for VOCERYQ in Adults with Recurrent Respiratory Papillomatosis

$PFE Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases Starna to receive an upfront payment of $330M businesswire.com/news/home/2…


$ABVX remained the most crowded long among our 121 tracked biotech specialist managers in Q3 2026, with 43 reporting holders. $RVMD and $COGT ranked 2nd and 3rd, respectively. Still waiting on a few late filers & stragglers, and have a couple to add manually, but the top three from Q2 held their spots. $TNGX $AVTX $ELVN $ERAS $ORIC $SYRE $MLYS $VERA $XENE

$RZLT PT raised to $10 at Wedbush

$NVO launches the new Novocare: Free support program connects people with Wegovy in addition to home delivery, everyday support, wellness partners and rewards. $LLY prnewswire.com/news-releases…

$SNTI 1-for-33 reverse split

$KPTIQ Karyopharm FDA Accepts sNDA for XPOVIO (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis PDUFA 06/28/27

$PRAX upgraded to Overweight at Wells Fargo. PT $509

$LXEO announces positive interim data from the HEROIC-PKP2 Phase I/II trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) finance.yahoo.com/healthcare…

$HELP Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in MDD -7.6 point placebo-adjusted change from baseline at Week 6 for the primary endpoint on the MADRS (p< 0.0001)

$IVVD DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently. Q3 PEMGARDA net product revenue $15.4M Cash and cash equivalents were $126.4M

$HELP Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in MDD -7.6 point placebo-adjusted change from baseline at Week 6 for the primary endpoint on the MADRS (p< 0.0001)

$CRDF Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer